CA2914025C - Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor - Google Patents

Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor Download PDF

Info

Publication number
CA2914025C
CA2914025C CA2914025A CA2914025A CA2914025C CA 2914025 C CA2914025 C CA 2914025C CA 2914025 A CA2914025 A CA 2914025A CA 2914025 A CA2914025 A CA 2914025A CA 2914025 C CA2914025 C CA 2914025C
Authority
CA
Canada
Prior art keywords
inhibitors
limited
hexitol derivative
group
dianhydrogalactitol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2914025A
Other languages
English (en)
French (fr)
Other versions
CA2914025A1 (en
Inventor
Dennis M. Brown
Kent C. Shih
Richard Schwartz
Sareth KANEKAL
Howard A. Burris, Iii
William Garner
Anne STEINO
Jeffrey BACHA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Del Mar Pharmaceuticals BC Ltd
Original Assignee
Del Mar Pharmaceuticals BC Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Del Mar Pharmaceuticals BC Ltd filed Critical Del Mar Pharmaceuticals BC Ltd
Publication of CA2914025A1 publication Critical patent/CA2914025A1/en
Application granted granted Critical
Publication of CA2914025C publication Critical patent/CA2914025C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
CA2914025A 2013-05-31 2014-06-02 Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor Active CA2914025C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361829739P 2013-05-31 2013-05-31
US61/829,739 2013-05-31
PCT/US2014/040461 WO2014194312A2 (en) 2013-05-31 2014-06-02 Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brian tumor

Publications (2)

Publication Number Publication Date
CA2914025A1 CA2914025A1 (en) 2014-12-04
CA2914025C true CA2914025C (en) 2023-03-07

Family

ID=51989551

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2914025A Active CA2914025C (en) 2013-05-31 2014-06-02 Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor

Country Status (14)

Country Link
US (1) US11026914B2 (https=)
EP (1) EP3003321A4 (https=)
JP (3) JP2016520622A (https=)
KR (4) KR20230124765A (https=)
CN (1) CN105579044A (https=)
AU (2) AU2014273911B2 (https=)
BR (1) BR112015029989A2 (https=)
CA (1) CA2914025C (https=)
CL (1) CL2015003512A1 (https=)
IL (1) IL242853B (https=)
MX (1) MX382824B (https=)
SG (1) SG11201509837QA (https=)
TW (1) TW201536278A (https=)
WO (1) WO2014194312A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160067241A1 (en) * 2013-06-13 2016-03-10 Dennis M. Brown Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted naphthalimides such as amonafide for the treatment of immunological, metabolic, infectious, and benign or neoplastic hyperproliferative disease conditions
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
WO2016138542A1 (en) * 2015-02-28 2016-09-01 Cyprus Therapeutics, Inc. Methods for inhibiting tumors and drug resistance
US20190091195A1 (en) * 2015-09-10 2019-03-28 Del Mar Pharmaceuticals Use of dianhydrogalactitol and derivatives thereof in the treatment of glioblastoma, lung cancer, and ovarian cancer
AU2016382786A1 (en) * 2015-12-29 2018-07-19 Outlook Therapeutics, Inc. Buffered formulations of bevacizumab
US20200062839A1 (en) * 2017-05-01 2020-02-27 Del Mar Pharmaceuticals (Bc) Ltd. Use of dianhydrogalactitol or analogs and derivatives in combination with vegf inhibitors to treat cancer
US10624869B2 (en) 2017-05-08 2020-04-21 Stanislaw R. Burzynski Methods for the treatment of recurrent glioblastoma (RGBM)
US20180353446A1 (en) * 2017-06-07 2018-12-13 Ranedis Pharmaceuticals, Llc Compositions and methods of treating and/or preventing cancer
US11344521B2 (en) 2017-06-12 2022-05-31 Burzynski Research Institute, Inc. Methods for the treatment of leptomeningeal disease
AU2018282735A1 (en) * 2017-06-12 2020-02-06 Stanislaw R. Burzynski Methods for the treatment of leptomeningeal disease
TWI793165B (zh) 2017-09-11 2023-02-21 美商阿托薩醫療公司 製造及使用因多昔芬(endoxifen)之方法
WO2019211708A1 (en) * 2018-05-04 2019-11-07 Kashiv Biosciences, Llc Stable pharmaceutical compositions of dianhydrogalactitol
CN109337884B9 (zh) * 2018-12-21 2021-10-29 中国农业科学院北京畜牧兽医研究所 一种丙酮酸激酶基因及其应用
MX2022000203A (es) 2019-07-03 2022-03-22 Atossa Therapeutics Inc Composiciones de liberacion sostenida de endoxifeno.
KR102415193B1 (ko) 2020-04-16 2022-06-29 사회복지법인 삼성생명공익재단 벤즈브로마론을 유효성분으로 포함하는 뇌암 예방 또는 치료용 약학 조성물
US20230212571A1 (en) * 2020-06-08 2023-07-06 Neonc Technologies, Inc. Compositions and methods for delivering polynucleotides
CN114796522A (zh) * 2022-01-06 2022-07-29 宁波大学 一种靶向线粒体放大氧化应激的新型抗肿瘤纳米药物
WO2024039764A2 (en) * 2022-08-17 2024-02-22 Ohio State Innovation Foundation Epitranscriptomic analysis of glioma
KR20250052523A (ko) 2023-10-11 2025-04-21 서울대학교병원 재발성 뇌 종양 진단, 예방 또는 치료에서의 cxcr-4의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4785077A (en) 1986-05-05 1988-11-15 Scripps Clinic And Research Foundation Substantially pure cytotoxicity triggering factor
US4801575A (en) * 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5294430A (en) * 1988-09-12 1994-03-15 University Of Rochester Use of dithiocarbamates to treat myelosuppression
CN107441493A (zh) * 2010-08-18 2017-12-08 德玛医药 制备用于改善未达最佳给药药物治疗的有效性和/或减少其副作用的药物的方法
BR112014017833A2 (pt) * 2012-01-20 2021-03-23 Dennis Brown Uso de hexitóis substituídos incluindo dianidrogalactitol e análogos para tratar doença neoplástica e células-tronco de câncer incluindo glioblastoma multiforme e meduloblastoma
US9814693B2 (en) * 2012-05-09 2017-11-14 Delmar Pharmaceuticals, Inc. Veterinary use of dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol to treat malignancies

Also Published As

Publication number Publication date
US20160158186A1 (en) 2016-06-09
KR20210100754A (ko) 2021-08-17
KR20230124765A (ko) 2023-08-25
MX382824B (es) 2025-03-13
IL242853B (en) 2022-03-01
AU2019283893A1 (en) 2020-01-23
EP3003321A2 (en) 2016-04-13
BR112015029989A2 (pt) 2017-08-22
CA2914025A1 (en) 2014-12-04
AU2014273911A1 (en) 2016-01-07
CN105579044A (zh) 2016-05-11
US11026914B2 (en) 2021-06-08
EP3003321A4 (en) 2017-01-18
WO2014194312A3 (en) 2015-02-05
TW201536278A (zh) 2015-10-01
MX2015016404A (es) 2016-09-28
JP2016520622A (ja) 2016-07-14
AU2014273911B2 (en) 2019-09-19
WO2014194312A2 (en) 2014-12-04
CL2015003512A1 (es) 2016-09-09
JP2020079259A (ja) 2020-05-28
KR20160065776A (ko) 2016-06-09
KR20220080199A (ko) 2022-06-14
AU2019283893B2 (en) 2022-03-24
SG11201509837QA (en) 2015-12-30
JP2022088616A (ja) 2022-06-14

Similar Documents

Publication Publication Date Title
AU2019283893B2 (en) Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor
US12336993B2 (en) Therapeutic benefit of suboptimally administered chemical compounds
US20210251944A1 (en) Methods for treating a cancer resistant to at least one tyrosine kinase inhibitor
AU2017251718B2 (en) Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multforme and medulloblastoma
US20150087687A1 (en) Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
AU2024200718A1 (en) Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol
BR112017009845A2 (en) dianhydrogalactitol together with radiation to treat non-small cell lung carcinoma and glioblastoma multiforme
HK1224581A1 (en) Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brian tumor

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190531

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251224

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260320

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260407